Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial

BACKGROUND: Giant cell tumor of bone (GCTB) is a rare primary bone tumor, characterized by osteoclast-like giant cells that express receptor activator of nuclear factor-kappa B (RANK), and stromal cells that express RANK ligand (RANKL), a key mediator of osteoclast activation. A RANKL-specific inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, T., Morioka, H., Nishida, Y., Kakunaga, S., Tsuchiya, H., Matsumoto, Y., Asami, Y., Inoue, T., Yoneda, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576909/
https://www.ncbi.nlm.nih.gov/pubmed/26205395
http://dx.doi.org/10.1093/annonc/mdv307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576909/
https://www.ncbi.nlm.nih.gov/pubmed/26205395
http://dx.doi.org/10.1093/annonc/mdv307

Ejemplares similares